Clinical trials: sponsored by Genentech, Inc.
Hepatic Impairment
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
This open-label study will evaluate the effect on the pharmacokinetics (PK), safety, and tolerability of a single oral dose of inavolisib in participants with moderate or severe hepatic impairment compared with demographically…
- Trial name
- NCT07144111
- Testing
- Inavolisib
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study of RO7890597 in Healthy Adult Volunteers
This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers.
- Trial name
- NCT07797478
- Testing
- RO7890597, Rabeprazole, Itraconazole
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system…
- Trial name
- NCT07214766
- Testing
- Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.
- Trial name
- NCT07329972
- Testing
- ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh…
- Trial name
- NCT06734208
- Testing
- Divarasib
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants
This is a Phase 1, open-label, randomized, two-part study to evaluate the relative bioavailability (rBA) of two tablet formulations compared to the capsule formulation of ZN-A-1041 (Part 1).
- Trial name
- NCT07051993
- Testing
- ZN-A-1041
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.
- Trial name
- NCT07025577
- Testing
- Immunoglobulin G
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants
This is a phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of rifampin on the pharmacokinetics (PK) and safety of divarasib in healthy participants.
- Trial name
- NCT06835465
- Testing
- Divarasib, Rifampin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants
This is a Phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of Itraconazole on the pharmacokinetics (PK) and safety of Divarasib in healthy participants.
- Trial name
- NCT06690138
- Testing
- Divarasib, Itraconazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.
- Trial name
- NCT06462118
- Testing
- Astegolimab
- Where
- 3 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
This is a Phase 1, open-label, two-period, one-sequence, crossover drug-drug interaction study to assess the P-gp and BCRP inhibition potential of divarasib using digoxin and rosuvastatin as probe substrates, respectively, in…
- Trial name
- NCT06677957
- Testing
- Digoxin, Divarasib, Rosuvastatin
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Amyotrophic Lateral Sclerosis
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential.
- Trial name
- NCT03237741
- Testing
- Reference capsule GDC-0134, Prototype capsule GDC-0134, rabeprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of…
- Trial name
- NCT04680273
- Testing
- [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteer
A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
This will be a single-center, open-label, 3 part study. The study is designed to determine the relative bioavailability of GDC-0980 capsule and tablet formulations under fasting conditions, the effects of a high-fat (fed) meal on…
- Trial name
- NCT01287091
- Testing
- GDC-0980, rabeprazole
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer Disease
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of [18F]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.
- Trial name
- NCT04394845
- Testing
- [18F]GTP1
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
This study will be an open-label, randomized, three-period, six-sequence crossover study of GDC-9545 administered to healthy females of non-childbearing potential to determine the relative bioavailability of the Phase 3 capsule…
- Trial name
- NCT04274075
- Testing
- GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Solid Tumor
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
This study will evaluate the bioavailability, palatability, safety and tolerability of entrectinib in healthy volunteers. Part 1 of the study will explore the performance of entrectinib multi-particle formulation.
- Trial name
- NCT03961100
- Testing
- Entrectinib 600 mg (T1), Entrectinib 600 mg (T2), Entrectinib 200 mg (R)
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
This is a two-part study to determine the relative bioavailability of two different prototype capsules of GDC-0134 to that of an existing reference capsule of GDC-0134 under both fed and fasted conditions.
- Trial name
- NCT03807739
- Testing
- GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.